Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Anastasia Zagoruyko HeartBeam (NASDAQ: BEAT ) stock is rocketing higher on Thursday as investors react to news of a new heart monitor patent . This new patent covers a 12-lead electro...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced issuance of its patent for a 12-lead electrocardiogram (“ECG”) patch monitor intended for detectio...
HeartBeam ( NASDAQ: BEAT ) is trading 54% higher premarket after it received patent for a 12-lead electrocardiogram (ECG) patch monitor to detect acute coronary syndrome and cardiac arrhythmia by the United States Patent and Trademark Office. The compan...
Patent Opens Pathway to a Disruptive Ischemia and Arrhythmia Detection ECG Patch Product HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced ...
HeartBeam (NASDAQ: BEAT) , a developmental stage digital health care company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will host a virtual roadshow webinar. During the event, scheduled to take place at 4:30 p.m. ET on Tuesday, Sept....
Unveils New Video Featuring the HeartBeam AIMI™ and AIMIGo™ Technology HeartBeam, Inc . (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced that it will ...
HeartBeam ( NASDAQ: BEAT ) on Tuesday said it was seeking a U.S. FDA approval for its platform technology used in detecting and diagnosing heart attacks. The company submitted a so-called 510(k) application to FDA for the HeartBeam AIMI platform technology. The HeartBeam t...
Submission Seeks Approval for the Company’s Proprietary ECG Technology to Aid in Diagnosis of Heart Attack in $500 million Total Addressable Market 18+ million People in the US have Coronary Artery Disease and Heart Attacks Occur Every 40 Seconds HeartBeam, ...
HeartBeam, Inc. (BEAT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Jon Hunt - Chief Business Officer Rick Brounstein - Chief Financial Officer Conference Call Par...
The following slide deck was published by HeartBeam, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: HeartBeam, Inc. 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...